Interactive Financial Charts Not Available

Regeneron (REGN) | Financial Analysis & Statements

Regeneron Pharmaceuticals, Inc. | Large-cap | Healthcare

$563.00

0.57%

Regeneron vs Vertex Regeneron vs Alnylam Regeneron vs Royalty Pharma plc Regeneron vs Insmed Regeneron vs Incyte Regeneron vs S&P 500 | Market

TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Mar 2025

Income Metrics

Revenue 3.0B

Gross Profit 2.6B 84.67%

Operating Income 591.7M 19.54%

Net Income 808.7M 26.70%

EPS (Diluted) $7.27

Balance Sheet Metrics

Total Assets 37.5B

Total Liabilities 8.2B

Shareholders Equity 29.4B

Debt to Equity 0.28

Cash Flow Metrics

Operating Cash Flow 1.4B

Free Cash Flow 773.6M

Revenue & Profitability Trend

Interactive Financial Charts Not Available

This page uses interactive financial charts and dynamic data visualization tools that require JavaScript. For detailed financial analysis:

Available Financial Data:

Income statements (annual and quarterly)
Balance sheets with asset and liability details
Cash flow statements and free cash flow analysis
Key financial ratios and performance metrics
Peer comparison and industry benchmarking

All financial data is displayed in accessible table format below. Use the table headers and structure to analyze trends and compare metrics across different periods.

Regeneron Income Statement From 2020 to 2024

Metric	2024	2023	2022	2021	2020
Revenue i	14.2B	13.1B	12.2B	16.1B	8.5B
Cost of Goods Sold i	2.0B	1.8B	1.6B	2.4B	1.1B
Gross Profit i	12.2B	11.3B	10.6B	13.6B	7.4B
Gross Margin % i	86.1%	86.2%	87.2%	84.8%	86.8%
Operating Expenses
Research & Development i	5.2B	4.4B	3.6B	2.9B	2.7B
Selling, General & Administrative i	3.0B	2.6B	2.1B	1.8B	1.3B
Other Operating Expenses i	53.4M	-2.1M	-89.9M	-45.6M	-280.4M
Total Operating Expenses i	8.2B	7.1B	5.6B	4.6B	3.8B
Operating Income i	4.0B	4.2B	5.0B	9.0B	3.6B
Operating Margin % i	28.1%	32.3%	41.0%	56.0%	42.1%
Non-Operating Items
Interest Income i	711.4M	495.9M	160.1M	45.8M	-
Interest Expense i	55.2M	73.0M	59.4M	57.3M	56.9M
Other Non-Operating Income	133.0M	-456.8M	-235.9M	342.5M	290.7M
Pre-tax Income i	4.8B	4.2B	4.9B	9.3B	3.8B
Income Tax i	367.3M	245.7M	520.4M	1.3B	297.2M
Effective Tax Rate % i	7.7%	5.9%	10.7%	13.4%	7.8%
Net Income i	4.4B	4.0B	4.3B	8.1B	3.5B
Net Margin % i	31.1%	30.1%	35.6%	50.2%	41.3%
Key Metrics
EBITDA i	5.2B	5.1B	5.5B	9.3B	4.1B
EPS (Basic) i	$40.90	$37.05	$40.51	$76.40	$32.65
EPS (Diluted) i	$38.34	$34.77	$38.22	$71.97	$30.52
Basic Shares Outstanding i	107900000	106700000	107100000	105700002	107600002
Diluted Shares Outstanding i	107900000	106700000	107100000	105700002	107600002

Income Statement Trend

Regeneron Balance Sheet From 2020 to 2024

Metric	2024	2023	2022	2021	2020
Assets
Current Assets
Cash & Equivalents i	2.5B	2.7B	3.1B	2.9B	2.2B
Short-term Investments i	6.5B	8.1B	4.6B	2.8B	1.4B
Accounts Receivable i	6.2B	5.7B	5.3B	6.0B	4.1B
Inventory i	3.1B	2.6B	2.4B	2.0B	1.9B
Other Current Assets	349.2M	386.6M	411.2M	332.4M	160.8M
Total Current Assets i	18.7B	19.5B	15.9B	14.0B	9.8B
Non-Current Assets
Property, Plant & Equipment i	1.5B	1.4B	1.3B	1.2B	1.0B
Goodwill i	1.1B	1.0B	915.5M	6.7M	-
Intangible Assets i	1.1B	1.0B	915.5M	-	-
Long-term Investments	-	-	-	-	-
Other Non-Current Assets	4.5B	3.0B	2.1B	1.1B	1.0B
Total Non-Current Assets i	19.1B	13.6B	13.3B	11.4B	7.4B
Total Assets i	37.8B	33.1B	29.2B	25.4B	17.2B
Liabilities
Current Liabilities
Accounts Payable i	789.5M	606.6M	589.2M	564.0M	475.5M
Short-term Debt i	-	-	-	719.7M	-
Current Portion of Long-term Debt	-	-	-	-	-
Other Current Liabilities	-	-	-	-	122.4M
Total Current Liabilities i	3.9B	3.4B	3.1B	3.9B	2.7B
Non-Current Liabilities
Long-term Debt i	2.7B	2.7B	2.7B	2.0B	2.7B
Deferred Tax Liabilities i	-	-	-	-	-
Other Non-Current Liabilities	1.6B	854.1M	638.0M	680.2M	687.1M
Total Non-Current Liabilities i	4.5B	3.7B	3.4B	2.7B	3.4B
Total Liabilities i	8.4B	7.1B	6.6B	6.7B	6.1B
Equity
Common Stock i	100.0K	100.0K	100.0K	100.0K	100.0K
Retained Earnings i	31.7B	27.3B	23.3B	19.0B	10.9B
Treasury Stock i	15.2B	12.6B	10.4B	8.3B	6.6B
Other Equity	-	-	-	-	-
Total Shareholders Equity i	29.4B	26.0B	22.7B	18.8B	11.0B
Key Metrics
Total Debt i	2.7B	2.7B	2.7B	2.7B	2.7B
Working Capital i	14.7B	16.1B	12.7B	10.1B	7.1B

Balance Sheet Composition

Regeneron Cash Flow Statement From 2020 to 2024

Metric	2024	2023	2022	2021	2020
Operating Activities
Net Income i	4.4B	4.0B	4.3B	8.1B	3.5B
Depreciation & Amortization i	482.9M	421.0M	341.4M	286.2M	235.9M
Stock-Based Compensation i	982.8M	885.0M	725.0M	601.7M	432.0M
Working Capital Changes i	-210.8M	26.0M	-94.7M	-1.7B	-1.6B
Operating Cash Flow i	4.9B	4.4B	5.1B	7.7B	2.7B
Investing Activities
Capital Expenditures i	20.1M	-	-	-	-
Acquisitions i	-16.5M	-54.9M	-230.3M	0	-
Investment Purchases i	-16.6B	-11.6B	-7.5B	-7.0B	-3.2B
Investment Sales i	15.0B	9.4B	5.6B	2.2B	3.8B
Investing Cash Flow i	-1.6B	-2.3B	-2.4B	-4.8B	544.0M
Financing Activities
Share Repurchases i	-3.6B	-2.9B	-2.5B	-2.7B	-6.5B
Dividends Paid i	-	-	-	-	-
Debt Issuance i	-	-	0	0	3.5B
Debt Repayment i	-	-	0	0	-1.5B
Financing Cash Flow i	-2.2B	-1.8B	-1.0B	-1.0B	-2.0B
Free Cash Flow i	3.5B	3.7B	3.4B	6.5B	2.0B
Net Change in Cash i	1.2B	398.9M	1.7B	1.9B	1.3B

Cash Flow Trend

Regeneron Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 14.21

Forward P/E 12.45

Price to Book 1.96

Price to Sales 4.20

PEG Ratio 12.45

Profitability Ratios

Profit Margin 31.37%

Operating Margin 29.64%

Return on Equity 15.34%

Return on Assets 6.66%

Financial Health

Current Ratio 4.60

Debt to Equity 9.04

Beta 0.33

Per Share Data

EPS (TTM) $39.69

Book Value per Share $287.55

Revenue per Share $133.03

Peer Financial Comparison

Company	Market Cap	P/E Ratio	P/B Ratio	ROE	Profit Margin	Debt/Equity
regn	59.8B	14.21	1.96	15.34%	31.37%	9.04
Vertex	94.0B	26.03	5.47	22.77%	31.86%	8.89
Alnylam	57.5B	-201.34	229.45	-257.83%	-12.96%	1,093.31
Royalty Pharma plc	21.6B	16.16	2.52	17.29%	44.28%	84.40
Insmed	23.2B	-19.67	18.51	-160.54%	-259.82%	59.14
Incyte	15.3B	18.53	3.65	24.30%	18.99%	1.02

Financial data is updated regularly. All figures are in the company's reporting currency.